Author:
Shore Neal D.,Fizazi Karim,Tammela Teuvo L.J.,Luz Murilo,Salas Manuel Philco,Ouellette Paul,Lago Sérgio,Bastos Diogo Assed,Jansz G. Kenneth,Cárcano Flavio Mavignier,Andrade Lívia,Pliskin Marc,Lazaretti Nicolas,Arruda Larissa,Correa Ochoa José Jaime,Kuss Iris,Kappeler Christian,Sarapohja Toni,Smith Matthew
Reference16 articles.
1. Bayer AG. Nubeqa (darolutamide). Summary of product characteristics. 〈https://www.ema.europa.eu/en/documents/product-information/nubeqa-epar-product-information_en.pdf〉 (accessed 26 May 2023).
2. Bayer HealthCare Pharmaceuticals, Inc. Nubeqa (darolutamide). Prescribing information. 〈https://labeling.bayerhealthcare.com/html/products/pi/Nubeqa_PI.pdf〉 (accessed 26 May 2023).
3. Darolutamide in nonmetastatic, castration-resistant prostate cancer;Fizazi;N Engl J Med,2019
4. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide;Fizazi;N Engl J Med,2020
5. Trends in the crossover of patients in phase III oncology clinical trials in the USA;Yeh;Ecancermedicalscience,2020